[ad_1] Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual […]
Tag: Halozyme Therapeutics
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
[ad_1] SAN DIEGO, Nov. 6, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), today announced the pricing of $650 million aggregate principal amount of 0% convertible senior notes due 2031 (the […]
